The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC).
Edward B. Garon
Research Funding - Lilly
Jyoti D. Patel
No relevant relationships to disclose
Scott Myrand
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Tuan Nguyen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Craig H. Reynolds
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - Lilly
David R. Spigel
Consultant or Advisory Role - Lilly
Robert C. Hermann
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Lilly; Roche/Genentech
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Susan C. Guba
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ramaswamy Govindan
Consultant or Advisory Role - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Honoraria - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly
Philip Bonomi
Consultant or Advisory Role - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly